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Platelet and Leukocyte Activation During Aortoiliac Angiography
and Angioplasty
J. Barani, A. Gottsa¨ter∗, I. Mattiasson and B. Lindblad
Department of Vascular Diseases, University of Lund, University Hospital MAS, S-205 02 Malmo¨, Sweden
Objective: to evaluate platelet and leukocyte activation during aortoiliac angiography and percutaneous transluminal
angioplasty (PTA).
Methods: an observational study of 14 patients with aortoiliac atherosclerotic disease, nine of whom underwent PTA.
The proportion of fibrinogen-, and P-selectin positive platelets, P-selectin expression on platelets, intraplatelet cGMP and
cAMP, CD18 positive granulocytes, CD18 expression on granulocytes, plasma (p)-neopterin, p-TNF alpha and p-
interleukin-6 were repeatedly measured in arterial blood during angiography and in venous blood before and after.
Results: compared to a previous venous sample, arterial intraplatelet cAMP was increased proximal to the atherosclerotic
lesion before contrast infusion and PTA (median 18 [range: 14–22] vs 16 [15–21] pmol/109 platelets; p<0.05), and
intraplatelet cGMP was increased proximal to the lesion after contrast infusion and PTA (1.2 [0.8–3.9] vs 0.9
[0.6–2.5] pmol/109 platelets; p<0.05). Four hours after angiography, both the proportion of P-selectin positive platelets
(28 [11–55]%) and platelet P-selectin expression (9 [6–40]) had decreased (p<0.05), from arterial values distal to the
lesion before contrast infusion and PTA (57 [24–78]% and 26 [10–83]). Granulocyte CD18 expression was lower during
angiography than in a previous venous sample.
Conclusions: the results are compatible with platelet but not leukocyte activation during peripheral angiography.
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Introduction decreased after percutaneous transluminal angioplasty
(PTA) of peripheral vessels,17 but was unchanged,18 or
Angiography with angioplasty may expose pro- increased18,19 after PTCA. CD18 levels after PTCA are
coagulant and proinflammatory subendothelial struc- dependent upon restenosis,18 and platelet membrane
tures.1,2 This may aggravate the platelet and leukocyte activation markers has been suggested as predictors
activation in atherosclerotic disease3 leading to throm- of this outcome.20
bosis and restenosis.4–7 Platelet antiaggregation and vasodilatation are in-
Several platelet and leukocyte mechanisms might duced by endothelial nitric oxide (NO) and pro-
be activated. Levels of P-selectin,8,9 mediating platelet- stacyclin (PGI2) production, via cyclic guanosine
leukocyte binding,10 are increased in coronary artery monophosphate (cGMP) and cyclic 3′–5′adenosine
disease (CAD), and leukocyte-platelet interactions are monophosphate (cAMP), respectively.21,22 cGMP levels
increased after percutaneous transluminal coronary increase in coronary blood23 after PTCA, whereas
angioplasty (PTCA).11 In coronary blood, both ex- cAMP levels are unchanged.23
pression of the activated platelet fibrinogen receptor12 Leukocytes secrete inflammatory mediators such
and release of chemoattractants affecting neutrophils13 as interleukin (Il)-6,24 TNF-alpha,25 and neopterin.26
increase after PTCA, indicating activation of platelets Increased neopterin levels in atherosclerosis26 reflect
and neutrophils.14 monocyte and macrophage hyperactivity.27–29 Neo-
The granulocyte membrane complex CD18 is of pterin is linked to NO synthesis as it is a marker for
importance for leukocyte-endothelial adhesion, which the synthesis of tetrahydrobiopterin,30 a co-enzyme for
is increased in unstable CAD.15,16 CD18 expression inducible NO-synthase.30–32
We repeatedly evaluated arterial platelet and leu-
∗ Please address all correspondence to: A. Gottsa¨ter, University of kocyte activation during peripheral angiography andLund, Department of Vascular Diseases, University Hospital MAS,
S-205 02 Malmo¨, Sweden. PTA in 14 patients with aortoiliac atherosclerosis.
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Material and Methods cytometry (Coulter Epics XL, Coulter Electronics, Hia-
leah, FL, U.S.A.) using commercialy available reagents
Material (Table 1) (Dakopatts AB, A¨lvsjo¨, Sweden, and Biopool Inter-
national, Umea˚, Sweden) and expressed as per-
Fourteen patients with aortoiliac atherosclerotic dis- centages. The P-selectin expression on platelets and
CD18 expression on granulocytes were determined byease and clinical indication for angiography were in-
cluded. All patients received intravenous contrast flow cytometry using commercially available reagents
(Dakopatts AB, A¨lvsjo¨, Sweden) and expressed asinfusion (Hexabrix⊂, Gothia, Billdal, Sweden [n=11]
or Omnipaque⊂, Nycomed, Lidingo¨, Sweden [n=3]), mean channel fluorescence intensity (MFI).
whereas 9/14 were subjected to PTA.
Platelet activation was assessed by measurements
of the proportion of platelets positive for fibrinogen
P-TNF alpha and p-interleukin-6 analysisand P-selectin, P-selectin expression on platelets, and
measurements of intraplatelet cGMP and cAMP. Leu-
P-TNF alpha and p-interleukin-6 were measured bykocyte activation was assesed by measurements of the
ELISA using commercially available test kits (Phar-proportion of granulocytes positive for CD18, CD18
mingen, San Diego, CA, U.S.A.) according to pro-expression on granulocytes, plasma (p)-neopterin, p-
cedures described by the manufacturer.TNF alpha, and p-Il-6. The following samples were
taken: a venous sample before angiography, arterial
samples before and after contrast infusion and PTA
proximal and distal to the atherosclerotic lesion. Un-
Plasma neopterin analysisfortunately, samples taken after contrast infusion and
PTA distal to the atherosclerotic lesion could not be
P-neopterin was determined by ELISA according toevaluated for technical reasons. In addition, venous
procedures described by the manufacturer (Henning,blood samples were taken 4 and 24 h after angiography
Berlin, Germany). Intra- and interassay coefficients ofin 6/14 patients.
variation were 1.7% and 8.2%, respectively.All participants had given informed consent to the
study, which was approved by the ethics committee
of the University of Lund.
Intraplatelet cyclic nucleotide analysis
Methods
The method used for platelet preparation has been
described in detail.34 Intraplatelet cGMP and cAMPBody mass index (BMI) was calculated as weight (kg)/
were measured by RIA kits (Amersham Pharmaciaheight (m)2. Blood and ankle pressures were measured
Biotech AB, Uppsala, Sweden) cGMP I125 assay systemwith the patient in the supine position.
RPA 525 and cAMP I125 assay system RPA 509). The
results are given as pmol/109 platelets. Intra-assay
coefficients of variation were 7.2% for cGMP and 6.4%Laboratory analyses
for cAMP. Inter-assay coefficients of variation for a
single sample analysed three times in five successiveBlood haemoglobin, leukocyte and platelet counts,
assays were 3.1% for cGMP and 8.6% for cAMP.and serum (s-)creatinine was determined by routine
laboratory methods. Venous p-glucose was determined
by a routine hexokinase method. S-triglycerides and
S-total-, and LDL- and HDL-cholesterol were de-
Statisticstermined33 on a DAX 48 automatic analyser (Bayer AB,
Gothenburg, Sweden).
Results are presented as median (ranges). Non-para-
metric statistics were used throughout the calculations.
Differences between test occasions were evaluatedFlow cytometry analysis
with Wilcoxon’s signed-rank test, p-values of <0.05
were considered significant. StatView 4.5 (Abacus Con-The proportion of activated platelets positive for fib-
rinogen and P-selectin, and the proportion of gran- cepts Inc., Berkeley, CA, U.S.A.) was used for statistical
calculations.ulocytes positive for CD18 were determined by flow
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Table 1. Background data of patients (n=14, 7 males) with ath-
erosclerotic vascular disease undergoing angiography. Median
(range) or n (%).
Age (years) 72(50–94)
Body mass index (kg/m2) 28.5(21.7–33.9)
Blood pressure (mmHg) 148(114–180)/82(60–115)
Right ankle pressure (mmHg) 100(35–155)
Left ankle pressure (mmHg) 85(40–220)
Blood haemoglobin (g/l) 133(106–161)
Blood leukocytes (×109/l) 9.2(6.4–12.2)
Blood platelet count (×109/l) 269(160–494)
Serum creatinine (micromol/l) 88(66–202)
Serum total cholesterol (mmol/l) 5.2(3.2–9.2)
Serum LDL cholesterol (mmol/l) 3.1(1.4–7.1)
Serum HDL cholesterol (mmol/l) 1.1(0.6–1.6)
LDL/HDL ratio 2.5(1.8–6.5)
Serum triglycerides (mmol/l) 2.1(1.0–4.6)
Leg ulcer or rest pain (n [%]) 6(43)
Previous ischaemic heart disease (n [%]) 5(36)
Previous stroke (n [%]) 3(21)
Antihypertensive treatment (n [%]) 8(57)
Diabetes treatment (n [%]) 5(36)
Lipid lowering treatment (n [%]) 4(29)
Antiplatelet treatment (n [%]) 10(71)
Amount of iodine administered (g) 33.9(10.4–47.8)
PTA performed during angiography
(n [%]) 9(64)
Stent placement during angiography
(n [%]) 7(50)
Results
Compared to the venous sample obtained before
angiography, intraplatelet cAMP was higher proximal
to the atherosclerotic lesion before contrast infusion
and PTA (Table 2 and Fig. 1) and intraplatelet cGMP
was higher proximal to the atherosclerotic lesion after
contrast infusion and PTA (Table 2). Granulocyte CD18
expression (MFI), on the other hand, was lower both
distal to the lesion before contrast infusion and PTA
and proximal to the lesion after contrast infusion and
PTA, compared to the venous sample (Table 2).
Before contrast infusion and PTA, the proportion of
fibrinogen positive platelets was higher distal to the
lesion compared to proximal to the lesion (Table 2).
Both the proportion of P-selectin positive platelets and
platelet P-selectin expression in the venous sample
obtained 4 h after angiography, compared to values
distal to the lesion before contrast infusion and PTA
(Table 2).
When the 9/14 patients that were subjected to PTA
were analysed separately, no statistically significant
changes were found in any of the study variables.
Due to the small patient numbers, the nine patients
subjected to PTA were not compared with the five Ta
b
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patients that underwent only angiography.
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this procedure. Some of the differences between our
and these results might be due to the fact that we
studied subjects undergoing angiography and PTA of
peripheral vessels, whereas most previous studies
have been performed in subjects undergoing coronary
angiography and PTCA.6,11–14,18,19 We report lower gran-
ulocyte expression of the adhesion molecule CD18
during angiography, which might be directly com-
pared with recent findings by Danielsson and co-
workers,17 who also reported a very limited white
blood cell response after PTA. The results of both
our and Danielsson’s studies indicate that differences
might exist between leukocyte responses to contrast
infusion and endothelial injury in coronary and peri-
pheral vessels. As we have made a relatively large
number of comparisons in a small number of patients,
there is a possibility that the significant changes are
caused by multiple testing.
In a previous report upon cGMP and cAMP levels
during PTCA,23 plasma cGMP levels were increased
distal to an arterial obstruction. We now confirm this
finding also for intraplatelet cGMP levels, useful in-
Fig. 1. Markers of platelet activation in 14 patients with aortoiliac dicators for measurements of circulating NO.35 The
atherosclerosis undergoing angiography. Nine patients were sub-
higher intraplatelet cAMP seen before contrast in-jected to PTA. Values are median, for ranges and significances please
see Table 2. Samples during angiography were taken proximal to fusion and PTA in our study can be compared to the
the atherosclerotic lesion and corresponds to samples numbered 2 increasing plasma cAMP reported by Kremastinos and
and 4 in Table 2.
co-workers in venous blood,23 thought to reflect stress
occurring during catheterisation.
Discussion The degree of platelet and granulocyte activation in
individual patients might have been influenced by for
In this study, we report higher intraplatelet levels of example different medications given, the presence of
cAMP and cGMP in arterial samples during angio- leg ulcers or rest pain in some patients, and differences
graphy compared to a previous venous blood sample in renal function. We therefore chose to report only
in patients with aortoiliac atherosclerotic disease. Fur- changes occurring in the whole group of 14 patients.
thermore, the proportion of fibrinogen positive plate- When the 9/14 patients subjected to PTA were ana-
lets was increased in arterial blood distal to the lysed separately, no statistically significant changes
atherosclerotic lesion, compared with values obtained were found in any of the study variables. It can there-
proximal to the lesion. The numeric increases in both fore not be concluded whether the observed changes
the proportion of P-selectin positive platelets and plate- were explained by the angioplasty, or by the contrast
let P-selectin expression (MFI) during angiography infusion, or by a combination of these factors. Whether
did not reach statistical significance, whereas both the choice of contrast agent influences platelet ag-
values decreased significantly during the first 4 h after gregation after balloon angioplasty has been tested,
angiography compared with values obtained during and no differences were found between iopamidol,
the procedure. Almost all granulocytes were CD18 diatrizoate, and ioxaglate.6 A mild increase in bound
positive already before angiography, however, gran- fibrinogen has been reported, however, for both ionic
ulocyte CD18 expression (MFI) was lower during and non-ionic, monomeric and dimeric contrast
angiography compared to the previous venous sample. media.7 It can therefore not be excluded that the con-
Our results are compatible with platelet-, but not trast infusion was responsible for some of the changes
leukocyte-, activation during PTA. Increases in both in the study variables observed during angiography.
the surface expression of the activated fibrinogen re- A previous comparison of indices of haematology
ceptor on platelets and CD11b on neutrophils,12 as well and coagulation in paired samples of arterial and
as increased release of chemoattractants13 have been venous blood from patients with arterial disease re-
reported in subjects undergoing PTCA, however, in- vealed no differences concerning P-selectin, von Wil-
lebrand factor, D-dimer, leukocyte elastase, fibrinogen,dicating both neutrophil and platelet activation after
Eur J Vasc Endovasc Surg Vol 23, March 2002
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during coronary angioplasty in humans. Circulation 1993; 88:tissue plasminogen activator or prothrombin or ac-
2728–2734.tivated partial thromboplastin time.36 Our data indicate 7 Laffan M, Dawson P, Gooding RP. A comparison between the
that neither do any such differences exist for the platelet activating properties of different contrast media used in
radiology and MRI. Br J Radiol 1997; 70: 798–804.variables in our study except for the arterial cAMP
8 Hamburger S, McEver R. GMP-140 mediates adhesion of stim-sample obtained proximal to the atherosclerotic lesion ulated platelet to neutrophils. Blood 1990; 75: 550–554.
before PTA, which was higher than in the venous 9 Warzok F, Steiner M, Blann AD et al. Immediate and late effects
of coronary angiography on soluble endothelial cell markers andsample, maybe reflecting stress occurring during cath-
P-selectin in patients with and without coronary artery disease.eterisation.23 All other differences between venous and Blood Coagul Fibrinol 1999; 10: 381–387.
arterial blood in our study occurred when the venous 10 Furman M, Benoit S, Barnard M et al. Increased platelet
reactivity and circulating monocyte-platelet aggregates insample was compared with arterial blood obtained
patients with stable coronary artery disease. J Am Coll Cardioleither distal to an atherosclerotic lesion, or after con- 1998; 31: 352–358.
trast infusion and, in some cases, PTA. 11 Mickelson J, Lakkis N, Villarreallevy G, Hughes B, Smith
C. Leukocyte activation with platelet adhesion after coronaryIn conclusion, during aortoiliac angiography arterial
angioplasty: a mechanism for recurrent disease? J Am Coll Cardiolintraplatelet cGMP and cAMP levels as well as the 1996; 28: 345–353.
proportion of fibrinogen positive platelets distal to the 12 Neumann F, Ott I, Gawaz M, Puchner G, Scho¨mig A. Neutro-
phil and platelet activation at balloon-injured coronary arteryatherosclerotic lesion are increased. After angiography,
plaque in patients undergoing angioplasty. J Am Coll Cardiolthe proportion of P-selectin positive platelets and plate-
1996; 27: 819–824.
let P-selectin expression (MFI) decrease. Arterial gran- 13 Neumann F-J, Richardt G, Schneider M et al. Cardiac release
of chemoattractants after ischaemia induced by coronary balloonulocyte CD18 expression (MFI) during angiography,
angioplasty. Br Heart J 1993; 70: 27–34.on the other hand, is lower than in a previous venous
14 DeServi S, Mazzone A, Ricevuti G et al. Granulocyte activation
sample. Our results are compatible with platelet, but after coronary angioplasty in humans. Circulation 1990; 82: 140–
146.not leukocyte activation during contrast infusion and
15 Mazzone A, DeServi S, Ricevuti G et al. Increased expressionPTA in peripheral arteries. The clinical relevance of this
of neutrophil and monocyte adhesion molecules in unstablephenomenon is unclear, however, and the hypothesis coronary artery disease. Circulation 1993; 88: 358–363.
needs to be tested further in a larger study. 16 DeServi S, Mazzone A, Ricevuti G et al. Clinical and an-
giographic correlates of leukocyte activation in unstable angina.
J Am Coll Cardiol 1995; 26: 1146–1150.
17 Danielsson P, Schatz P, Swartbol P et al. Response of in-
flammatory markers to balloon angioplasty in peripheral arterial
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